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Dominant-Negative Mutations in a-II Spectrin Cause
West Syndrome with Severe Cerebral Hypomyelination,
Spastic Quadriplegia, and Developmental Delay
Hirotomo Saitsu,1,* Jun Tohyama,2 Tatsuro Kumada,3 Kiyoshi Egawa,3 Keisuke Hamada,4 Ippei Okada,1
Takeshi Mizuguchi,1,17 Hitoshi Osaka,5 Rie Miyata,6 Tomonori Furukawa,3 Kazuhiro Haginoya,7
Hideki Hoshino,8 Tomohide Goto,9 Yasuo Hachiya,10 Takanori Yamagata,11 Shinji Saitoh,12
Toshiro Nagai,13 Kiyomi Nishiyama,1 Akira Nishimura,1 Noriko Miyake,1 Masayuki Komada,14
Kenji Hayashi,15 Syu-ichi Hirai,15 Kazuhiro Ogata,4 Mitsuhiro Kato,16 Atsuo Fukuda,3
and Naomichi Matsumoto1,*
A de novo 9q33.3-q34.11 microdeletion involving STXBP1 has been found in one of four individuals (group A) with early-onset West
syndrome, severe hypomyelination, poor visual attention, and developmental delay. Although haploinsufﬁciency of STXBP1 was
involved in early infantile epileptic encephalopathy in a previous different cohort study (group B), no mutations of STXBP1 were found
in two of the remaining three subjects of group A (one was unavailable). We assumed that another gene within the deletion might
contribute to the phenotype of group A. SPTAN1 encoding a-II spectrin, which is essential for proper myelination in zebraﬁsh, turned
out to be deleted. In two subjects, an in-frame 3 bp deletion and a 6 bp duplication in SPTAN1were found at the initial nucleation site of
the a/b spectrin heterodimer. SPTAN1was further screened in six unrelated individuals withWS and hypomyelination, but nomutations
were found. Recombinant mutant (mut) and wild-type (WT) a-II spectrin could assemble heterodimers with b-II spectrin, but a-II (mut)/
b-II spectrin heterodimers were thermolabile compared with the a-II (WT)/b-II heterodimers. Transient expression in mouse cortical
neurons revealed aggregation of a-II (mut)/b-II and a-II (mut)/b-III spectrin heterodimers, which was also observed in lymphoblastoid
cells from two subjects with in-frame mutations. Clustering of ankyrinG and voltage-gated sodium channels at axon initial segment
(AIS) was disturbed in relation to the aggregates, together with an elevated action potential threshold. These ﬁndings suggest that path-
ological aggregation of a/b spectrin heterodimers and abnormal AIS integrity resulting from SPTAN1mutations were involved in path-
ogenesis of infantile epilepsy.Introduction
West syndrome (WS) is a common infantile epileptic
syndrome characterized by brief tonic spasms, an electro-
encephalogram pattern called hypsarrhythmia, and
mental retardation.1 Brain malformations and metabolic
disorders can be underlying causes of WS, but many cases
remain etiologically unexplained.1 Only two causative
genes, ARX (MIM *300382) and CDKL5 (MIM *300203),
are mutated in a subset of familial and sporadic X-linked
WS cases (ISSX1 and ISSX2 [MIM #308350 and
#300672]).2–4 Early infantile epileptic encephalopathy
with suppression-burst (EIEE) is the earliest form of infan-
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The Ameoccurs in 75% of individuals with EIEE, suggesting
a common pathological mechanism between these two
syndromes.5,6 We have recently reported that de novo
mutations of STXBP1 (MIM *602926) cause EIEE.7
Spectrins are submembranous scaffolding proteins
involved in the stabilizationofmembraneproteins.8,9 Spec-
trins are ﬂexible and long molecules consisting of a and
b subunits, which are assembled in an antiparallel side-by-
side manner into heterodimers. Heterodimers form by
end-to-end tetramers integrating into themembrane cytos-
kelton.8,9 The spectrin repertoire in humans includes two
a subunits and ﬁve b subunits. Defects of erythroid a-I
and b-I spectrins and neuronal b-III spectrin are associated
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#270970 and þ182870]) and spinocerebellar ataxia type 5
(SCA5 [MIM#600224]), respectively.8,10,11 The a-II spectrin
is considered as themajor a spectrin expressed innoneryth-
roid cells, and a-II/b-II spectrin heterodimers are the
predominant species in these cells.9,12 Abnormal develop-
ment of nodes of Ranvier and destabilizing initial clusters
of voltage-gated sodium channels (VGSC) were observed
in zebraﬁsh a-II spectrin mutants harboring a nonsense
mutation. The mutants also showed impaired myelination
in motor nerves and in the dorsal spinal cord, suggesting
that a-II spectrin plays important roles in the maintenance
of the integrity of myelinated axons.13
Here, we describe three cases of early-onset WS with
cerebral hypomyelination harboring SPTAN1 (MIM
*182810) aberrations. Two individuals with in-framemuta-
tions showed more severe phenotypes than one individual
with SPTAN1 and STXBP1 deletion. In-frame mutations of
SPTAN1 result in aggregation of a-II (mut)/b-II and a-II
(mut)/b-III spectrin heterodimers, suggesting dominant-
negative effects of the mutations. Spectrin aggregation is
associated with disturbed clustering of VGSC and an
elevated action potential threshold. Our ﬁndings revealed
essential roles of a-II spectrin in human brain development
and suggest that abnormal AIS is possibly involved in path-
ogenesis of infantile epilepsy.Subjects and Methods
Subjects
Subjects 1, 2, and 3 have been originally reported as three of four
individuals with early onsetWS, severe hypomyelination, reduced
whitematter, and developmental delay (group A: subjects 1, 2, and
3 were previously named as No. 2, No. 1, and No. 3, respectively,
and No. 4 was unavailable for this study).14 Subject 1 has been
shown to possess a 9q33.3-q34.11 microdeletion including
STXBP1.7 Clinical information of these three subjectswith SPTAN1
aberrations is updated in Table S1 available online.We screened for
SPTAN1mutations in a total of eight unrelated individualswithWS
accompanied by severe hypomyelination without episodes of
prenatal incidentsorneonatal asphyxia (sixmales and two females,
including subjects 2 and 3 of group A). Individuals with these two
distinctive features (WS and severe hypomyelination) are relatively
rare. These eight patients were totally different from the previously
investigated 13 EIEE patients (group B).7 Screening tests for meta-
bolic disorders (lactate, amino acids, and uric organic acids) were
normal in all subjects. ARX and CDKL5 were not mutated in the
six male and two female patients, respectively. The diagnosis was
made on the basis of clinical features, including tonic spasms
with clustering, arrest of psychomotor development, and hypsar-
rhythmia on electroencephalogram, aswell as brainmagnetic reso-
nance imaging (MRI) ﬁndings. Experimental protocols were
approved by the Committee for Ethical Issues at Yokohama City
University School of Medicine. Informed consent was obtained
from all individuals included in this study, in agreement with the
requirements of Japanese regulations.
Mutation Analysis
Genomic DNA was obtained from peripheral blood leukocytes by
standard methods, ampliﬁed by GenomiPhi version 2 (GE Health-882 The American Journal of Human Genetics 86, 881–891, June 11,care, Buckinghamshire, UK), and used for mutational screening.
Exons 2 to 57, covering the SPTAN1 coding region (of transcript
variant 1, GenBank accession number NM_001130438), were
screened by high-resolution melting curve (HRM) analysis as
previously described.7 In transcript variant 2 (GenBank accession
number NM_003127), the only difference is that exon 37 of
variant 1 was missing. PCR conditions and primer sequences are
shown in Table S2. If a sample showed an aberrant melting curve
shift, the PCR product was sequenced. All mutations were also
veriﬁed on PCR products directly via genomic DNA (not ampliﬁed
by GenomiPhi) as a template. DNAs from 250 Japanese normal
controls were screened for the two in-frame SPTAN1 mutations
by HRM analysis. Normal controls which showed aberrant
melting curve shift were sequenced.Parentage Testing
For all families showing de novo mutations, parentage was
conﬁrmed by microsatellite analysis as previously described.7 Bio-
logical parentage was judged if more than four informative
markers were compatible and other uninformative markers
showed no discrepancies.Expression Vectors
A full-length human SPTAN1 cDNA was prepared by PCR with
ﬁrst-strand cDNA derived from a human lymphoblastoid cells
(LCL) and an IMAGE clone (clone ID 5211391) as a template.
The obtained SPTAN1 cDNA was sequenced and conﬁrmed to be
identical to a RefSeq mRNA (amino acids 1–2477, GenBank acces-
sion number NM_001130438) except for two synonymous base
substitutions that have been registered in dbSNP as rs2227864
and rs2227862. Site-directed mutagenesis via a KOD-Plus-Muta-
genesis kit (Toyobo, Osaka, Japan) was used to generate SPTAN1
mutants including c.6619_6621 del (p.E2207 del) and
c.6923_6928 dup (p.R2308_M2309 dup). A C-terminal Flag-tag
was introduced by PCR. All variant cDNAs were veriﬁed by
sequencing. C-terminal Flag-tagged WT and mutant SPTAN1
cDNAs were cloned into the pCIG vector15,16 to express C-
terminal Flag-tagged a-II spectrin as well as nuclear-localized
EGFP. WT and mutant SPTAN1 cDNAs were also cloned into the
pCAG-EGFP-C1 vector, in which EGFP gene and multiple cloning
sites of pEGFP-C1 vector (Clontech,Mountain View, CA) are intro-
duced into a CAG-promoter vector,15,16 to express N-terminal
EGFP-tagged a-II spectrin.
For protein expression in Escherichia coli, WT and mutant
SPTAN1 cDNAs (amino acids 1445–2477, the last eight spectrin
repeats and the EF hand domain) were cloned into pGEX6P-3
(GE Healthcare) to generate glutathione S-transferase (GST) fusion
proteins. Human SPTBN1 cDNAs (amino acids 1–1139, GenBank
accession number NM_003128, including the actin binding
domain and eight spectrin repeats) were prepared by PCR via
ﬁrst-strand cDNA derived from a human LCL, and were cloned
into pET-24a (Merck, Darmstadt, Germany) to generate His-tag
fusion proteins.Protein Expression, Puriﬁcation, and Binding Assay
Proteins were expressed in Escherichia coli BL21 (DE3). Bacteria
were grown at 37C in Lysogeny Broth media with 300 mg/ml
ampicillin to a density yielding an absorbance at 600 nm of 0.8.
Protein expressionwas then induced with 1mM isopropyl-b-D-thi-
ogalactoside (IPTG) at 20C overnight. Cells were collected by
centrifugation and lysed by sonication. Proteins were puriﬁed by2010
afﬁnity chromatography with Glutathione Sepharose High Perfor-
mance (GE Healthcare) for GST-a-II spectrin or HisTrap HP (GE
Healthcare) for b-II spectrin-His. a-II spectrins were further puri-
ﬁed by HiTrap Q HP (GE Healthcare) and Superdex-200 (GE
Healthcare) columns in a buffer containing 150 mM NaCl, 20
mM sodium phosphate buffer (pH 7.5), and 2 mM dithiothreitol
(DTT). b-II spectrin was further puriﬁed by Superdex-200 (GE
Healthcare) columns in a buffer containing 1 M NaCl, 20 mM
sodium phosphate buffer (pH 7.5), and 2 mM DTT.
For the GST pull-down assay to examine the assembly of a-II/b-II
heterodimers, 0.5 mMGST-a-II spectrin (WT, del mut, or dup mut)
or 1 mM GST were preincubated with 1 mM b-II spectrin-His for
1 hr at 4C with gentle agitation in binding buffer containing
150 mM NaCl, 20 mM sodium phosphate buffer (pH 7.5), and
2 mM DTT. The reaction mixture (100 ml) was transferred onto an
Ultrafree-MC (Millipore, Billerica, MA), containing 50 ml of a 75%
slurry of Glutathione Sepharose 4B equilibrated in binding buffer,
and incubated overnight at 4C. Unbound proteins were recovered
by centrifugationat 5003 g for 2min. Thebeadswerewashed three
times with the binding buffer. The bound molecules were eluted
with a buffer containing 100mMNaCl, 20mM sodium phosphate
buffer (pH 7.5), 5mMDTT, 1mMEDTA, and 50mM reduced gluta-
thione. The eluted fractions were analyzed by SDS-PAGE, and
protein bands were visualized by staining with Coomassie brilliant
blue. For the analytical gel ﬁltration experiments, 3.3 mMGST-a-II
spectrin (WT, del mut, or dup mut) were preincubated with or
without3.3mMb-II spectrin-His for3hr at 4Cwithgentle agitation
in a bindingbuffer containing150mMNaCl, 20mMsodiumphos-
phate buffer (pH 7.5), and 2 mM DTT. The samples were analyzed
by Superdex-200 column equilibrated in binding buffer. The eluted
fractions were analyzed by SDS-PAGE and protein bands were visu-
alized by staining with Coomassie brilliant blue.Structural Prediction
The structure of human a-II spectrin was predicted by homology
modeling with Phyre,17 based on sequence homology between
human a-II spectrin (1981–2315 aa) and chicken brain alpha spec-
trin (1662–1982 aa) (Protein data bank ID, 1U4Q).18 The structure
and positions of mutations were illustrated by PyMOL with the
crystal structure of 1U4Q.Circular Dichroism Measurements
For circular dichroism (CD) measurements, GST-a-II spectrin were
digested with human rhinovirus 3C protease at 4C, and then the
GST-tag was removed by afﬁnity chromatography with gluta-
thione sepharose 4B (GE Healthcare). We measured far-UV CD
spectra and estimated the secondary structure as previously
described.7 In brief, the experiments were performed in 20 mM
sodium phosphate buffer (pH 7.5) containing 150 mM NaCl,
2 mM DTT with or without 1 mM CaCl2, which stabilizes the
structure of the EF hand domain. a-II and b-II spectrin concentra-
tion was adjusted to 1.7 mM (without CaCl2) and 1.5 mM (with
CaCl2). Melting (transition midpoint) temperature (Tm) was calcu-
lated by ﬁtting a sigmoid-function equation with KaleidaGraph
(Synergy Software, Reading, PA). The data from three independent
experiments were averaged and the SD was calculated. Similar
results were obtained in the presence or absence of 1 mM CaCl2.Cell Culture, Transfection, and Immunoﬂuorescence
For primary neuronal cultures for immunoﬂuorescence, cortexes
dissected from mice (embryonic days 14 to 15) were dissociatedThe Amein 0.05% trypsin-EDTA solution (Invitrogen, Carlsbad, CA), and
triturated with a Pasteur pipette. The dissociated cells were plated
on 200 mg/ml poly-D-lysine (Millipore)/20 mg/ml laminin (Invitro-
gen)-coated glass coverslips at a density of 15,000 cells/cm2.
Expression vectors were introduced at the time of dissociation
by electroporation, with the Amaxa Mouse Neuron Nucleofector
kit (Lonza, Tokyo, Japan) according to themanufacturer’s protocol
(Program O-005), and 2 mg plasmid DNA per condition. After
cortical neurons attached to coverslips, the medium was changed
from normal medium (10% FBS in DMEM) to maintaining
medium (2% B27 and 1 3 penicillin-streptomycin-glutamine in
Neurobasal [Invitrogen]). Half of the medium was replaced with
an equal volume of maintaining medium every 4 days. LCLs
were grown in RPMI 1640 medium supplemented with 10% FBS,
1 3 antibiotic-antimycotic (Invitrogen), and 8 mg/ml tylosin
(Sigma, Tokyo, Japan) at 37C in a 5% CO2 incubator. For the
immunoﬂuorescence imaging study, LCLs were plated on coated
coverslips as described above for 3–6 hr.
Neurons and LCLs were ﬁxed with 2% paraformaldehyde in PBS
for 15 min and permeabilized with 0.1% Triton X-100 for 5 min.
For detection of VGSCs, cells were ﬁxed with methanol at
20C for 10 min. Cells were then blocked with 10% normal
goat serum for 30 min. Primary antibodies used for the study
were shown in ﬁgure legends. Secondary antibodies, highly puri-
ﬁed to minimize cross-reactivity, were used: Alexa-488-conjugated
goat anti-mouse, anti-rabbit, and anti-chicken (Invitrogen), and
Cy3-conjugated goat anti-mouse, anti-rabbit, and anti-chicken
(Jackson ImmunoResearch, West Grove, PA). Coverslips were
mounted with Vectashield (Vector Laboratories, Burlingame, CA)
that contained 4,6-diamidino-2-phenylindole (DAPI) and visual-
ized with an AxioCam MR CCD ﬁtted to Axioplan2 ﬂuorescence
microscope (Carl Zeiss, Oberkochen, Germany). We captured
images with Axio Vision 4.6 software (Carl Zeiss). Immunoﬂuores-
cence of aggregated mutant a/b spectrins was much brighter than
WT a/b spectrins, leading to constant short exposure time
compared with the WT. For detection of ankyrinG and VGSCs,
the exposure time was ﬁxed in a series of experiments in order
to enable direct comparison between different samples. For evalu-
ation of ankyrinG and VGSC expression, 50 isolated transfected
neurons were analyzed in each experiment, and representative
cells were photographed. The results were conﬁrmed at least in
three independent experiments.Electrophysiology
Mouse neocortices at embryonic day 15 were dissociated and
plated on poly-L-lysine-coated plastic coverslips (Cell desk LF,
MS-0113L; Sumitomo Bakelite, Tokyo, Japan) at a density of about
100,000 cells/cm2. 1 mg of expression vector for either WT, del
mut, or dup mut a-II spectrin was introduced at the time of disso-
ciation by electroporation with an Amaxa Mouse Neuron Nucleo-
fector kit (Lonza). Primary cortical neurons were cultured in
neurobasal medium supplemented with B27 and penicillin-strep-
tomycin-glutamine (Invitrogen). During the culture period,
one-half of the medium was changed every day. Whole-cell
patch-clamp recordings were obtained from mice neocortical
neurons at 9 days in vitro (DIV) neuronal culture. A coverslip
was assembled to recording chambers on the stages of upright
microscopes (Olympus, Tokyo, Japan) and continuously perfused
with oxygenated, standard artiﬁcial cerebrospinal ﬂuid (ACSF) at
a ﬂow rate of 2 ml/min and a temperature of 30C. The standard
ACSF solution contained the following (mM): 126 NaCl, 2.5 KCl,rican Journal of Human Genetics 86, 881–891, June 11, 2010 883
Figure 1. SPTAN1 Aberrations in Individ-
uals with West Syndrome and Cerebral
Hypomyelination
(A) Genomic rearrangements at 9q33.3-
q34.11 in subject 1. Top depicts chromo-
somal bands and genomic location (Mb)
from the p telomere (cen, toward the
centromere; tel, toward the telomere).
Our previous study by BAC array could
reveal the approximate size of the deletion
(2.0 Mb) (horizontal line above boxes).7
The deletion was newly analyzed by Affy-
metrix GeneChip 250K array and turned
out to be 2.25 Mb in size (chr9:128,236,
086-130,486,226) (UCSC genome browser
coordinate [version Mar. 2006]) (hori-
zontal line below boxes). Blue and red
boxes indicate old and renewed deletion
intervals, respectively. Five RefSeq genes
(ODF2, GLE1, SPTAN1, WDR34, and SET)
were newly found (in red box). The rear-
rangements include an unexpected 204
kb inversion (green arrow). Intact genomic
regions are shown in sky blue.
(B) Schematic representation of SPTAN1
(transcript variant 1) consisting of 57
exons (UTR and coding region are open
and ﬁlled rectangles, respectively). Exon
37 of transcript variant 1 is missing in
variant 2, the only difference between
the two transcripts. Two distinct muta-
tions were found at evolutionary con-
served amino acids in triple helical repeats
(spectrin repeats). All these mutations
occured de novo. Homologous sequences
were aligned with the CLUSTALW web
site. a-II spectrin consists of 22 domains
(numbered), including 20 spectrin repeats,
an SH3 domain, and an EF hand domain.
The mutations occurred within the last
four spectrin repeats, which are required
for a/b heterodimer association (bidirec-
tional arrow).1.25 NaH2PO4, 2.0 MgSO4, 2.0 CaCl2, 26.0 NaHCO3, and 20.0
glucose. The images of cells were acquired with Olympus BX51
or BX61 microscopes equipped with electron-multiplying CCD
(EMCCD) cameras, #C9100-13 or #C9100-02 (Hamamatsu Pho-
tonics, Hamamatsu, Japan), respectively. Transfected cells were
selected for recordings by their ﬂuorescence in the nucleus via
a 403 water-immersion objective lens (UMPlanFI, Olympus).
Membrane currents and membrane potentials were recorded
with an Axopatch 700A and 200B ampliﬁer, respectively. Signals
were low-pass ﬁltered at 10 kHz and digitized at 50 kHz by means
of Digidata 1332A data-acquisition system (Molecular Devices,
Tokyo, Japan). Passive membrane properties and action potentials
were recorded with patch pipettes (5.8–8.0 MU) ﬁlled with the
following intercellular solutions (in mM): 130 K-methanesulfonic
acid, 10 KCl, 2 MgCl2, 0.1 EGTA, and 10 HEPES (pH 7.3) with
KOH. For current clamp experiments, cells were held at 60 mV
by constant current injection as needed, and their ﬁring pattern
were recorded in response to sustained depolarizing current injec-
tions (500 ms duration, þ10 pA increments) to analyze the input-884 The American Journal of Human Genetics 86, 881–891, June 11,output relationship in each cell. A single action potential was also
evoked to determine their ﬁring threshold. The injection current
amplitude (10 ms duration) was increased in 2–10 pA increments
from a subthreshold to an intensity well beyond threshold.
Voltage-clamp studies for sodium currents were carried out with
patch pipettes (5.8–8.0 MU) ﬁlled with the following intercellular
solutions (mM): 145 tetraethylammonium-Cl, 15 NaCl, 2 MgCl2,
10 EGTA, 10 HEPES, 3 MgATP, and 0.4 GTP (pH 7.4) with NaOH.
Series resistance was usually below 20 MU and compensated by
70%–80%. The remaining linear capacitive and leakage currents
were subtracted off-line by scaling average traces recorded at
hyperpolarized voltages. Voltage-dependent inward sodium cur-
rents were elicited by 500 ms depolarizing steps in 5 mV incre-
ments from 90 to þ10 mV at a holding membrane potential of
90 mV. For measuring the inactivation protocol of sodium
currents, 500 ms long prepotentials started at – 90 mV and were
incremented by 5 mV steps while the command potential was
kept constant at 30 mV. The current elicited during each test
pulse was normalized to the maximal current (I/Imax). Statistical2010
Figure 2. Brain MRI of Subjects with SPTAN1
Aberrations at the Most Recent Developmental
Stages
(A–C) T2-weighted axial images through the
basal ganglia. Subject 1 (with a 2.25 Mb deletion)
showed only slightly reduced white matter (A).
By contrast, cortical atrophy and severe hypo-
myelination with strikingly reduced volume of
white matter were evident, especially in the
frontal lobes, in subjects with in-framemutations
(subjects 2 and 3) (B and C).
(D–I) T2-weighted axial images through the
brainstem/cerebellum (D–F) and T2- (G) or T1-
weighted midline sagittal images (H and I).
Compared with subject 1 (D and G), subjects 2
(E and H) and 3 (F and I) show a thinned and
shortened corpus callosum (arrowheads), severe
atrophy of the brainstem, and hypoplasia and/
or atrophy of the cerebellar hemispheres and ver-
mis (arrows). m, months.analyses were made with two-way repeated-measures ANOVA fol-
lowed by a Bonferroni post-test for analysis of the input-output
relationship and current amplitude at every voltage step. One-
way ANOVA followed by Dunnet’s posthoc test was applied for
threshold, peak current, kinetics of action potentials, and passive
membrane properties. The results are given as mean 5 SEM, and
threshold p value for statistical signiﬁcance was 0.05. Statistical
comparisons were performed with the Prism 4.0 (GraphPad soft-
ware, La Jolla, CA).Results
Identiﬁcation of SPTAN1 In-Frame Mutations
We previously reported a de novo 9q33.3-q34.11 microde-
letion involving STXBP1 in an individual with EIEE, who
transited afterward to WS at the age of 3 months (subject
1).7 Subject 1 was originally reported as one of four individ-
uals (group A) who showed early onset WS and severe cere-
bral hypomyelination (as patient No. 2).14 It is likely that
haploinsufﬁciency of STXBP1 caused EIEE and subsequent
WS in subject 1;7 however, no mutations of STXBP1 were
found in two of the remaining three individuals of group
A (subjects 2 and 3, previously described as No. 1 and No.
3, and No. 4 was unavailable for this study).14 Based on
obvious severe hypomyelination of the group A individ-
uals, we hypothesized that another gene within the dele-
tionmay contribute to thephenotype of groupA, especially
for severe hypomyelination. Re-examination of the dele-The American Journal of Htion interval by genomic microarray and
long PCR successfully determined the 2.25
Mbdeletion and the associated 204 kb inver-
sion (Figure 1A and see Figure S1). Among
the 46 genes mapped within the deletion,
SPTAN1, which encodes a-II spectrin, ap-
peared to be a primary candidate because ze-
braﬁsh a-II spectrin mutants showed
impaired myelination.13 We found de novo
heterozygous mutations in SPTAN1 insubjects 2 and 3 (parentage was conﬁrmed in their respec-
tive families). Subject 2 has an in-frame 3-bp deletion
(c.6619_6621 del) leading to p.E2207 del in the continuous
helix region between the last two spectrin repeats, and
subject 3 has an in-frame 6 bp duplication (c.6923_6928
dup, p.R2308_M2309 dup) within the last spectrin repeat
(Figure 1B). These two mutations were absent in 250 Japa-
nese normal controls (500 alleles). SPTAN1 was further
screened in six unrelated individuals with WS and hypo-
myelination similar to the phenotype of group A (not
belonging to group B), but no mutations were found.
Phenotypes Associated with SPTAN1 Aberrations
The clinical features of the three subjects with SPTAN1
aberrations are summarized in Table S1. Subjects 2 and 3
showed severe spastic quadriplegia, no developmental
progress, and poor visual attention. Epileptic seizures were
resistant to various treatments. Subject 3 died of fulmi-
nant myocarditis at 3 years of age. In contrast, subject 1
showed slight psychomotor development with eye con-
tact, but no head control. Her seizures have been well
controlled. Brain MRI of subjects 2 and 3 revealed wide-
spread brain atrophy including brainstem, hypoplasia,
and/or atrophy of the cerebellar hemispheres and ver-
mis, ventriculomegaly, a thinned and shortened corpus
callosum, and severe hypomyelination with strikingly
reduced white matter at 6 and 3 years of age, respectively
(Figure 2). Of note, while subject 1 initially showeduman Genetics 86, 881–891, June 11, 2010 885
Figure 3. Mutational Effects on the a-II/
b-II Spectrin Heterodimer
(A) Positions of the two mutations
(c.6619_6621del, p.E2207 del in blue;
c.6923_6928dup, p.R2308_M2309 dup in
purple) in the predicted human a-II spec-
trin structure. Domains 19–21 (the last
three spectrin repeats) are colored red,
yellow, and green, respectively.
(B) GST pull-down assay of a recombinant
GST-tagged a-II spectrin/b-II spectrin het-
erodimer. The WT and two mutant a-II
spectrins could form heterodimers with
b-II spectrin at comparable levels. b-II spec-
trin did not show any binding to GST
alone.
(C–F) CD spectra (C and D) and CD melt-
ing curves (E and F) at 222 nm of the WT,
del mut, and dup mut of a-II spectrins and
b-II spectrin as a monomer (C and E)
and as heterodimers of the WT, del mut,
and dup mut of a-II spectrins with b-II
spectrin (D and F). CD spectra showed
no difference in the helical content of
the WT and mutant a-II spectrin mono-
mers and heterodimers with b-II spectrin
(C and D). The WT and mutant a-II spec-
trin monomers are unfolded at 60C,
whereas b-II spectrin is unfolded around
at 50C (E). In contrast, dimers of WT
andmutant a-II spectrins with b-II spectrin
are partly dissociated and accompanied
with denaturation of a local part of
the monomers at 50C–60C (Tm [C]:
58.362 5 0.059 [WT], 55.617 5 0.047
[del mut], 57.110 5 0.077 [dup mut])
and completely unfolded at 70C–80C
(Tm [C]: 78.5155 0.327 [WT], 75.8135
0.115 [del mut], 75.267 5 0.469 [dup
mut]) (F). The thermostability of the heter-
odimers is obviously different between the
WT and the mutants. Each dot represents
the average of three repeated experiments;
error bars, SD.striking hypomyelination of cerebral cortex and thin
corpus callosum at 12 months of age,14 she completed
myelination and showed only slightly reduced white
matter at 4 years of age (Figure 2). The apparent differ-
ences of drug intractability and severity of cerebral hypo-
myelination and brainstem/cerebellum atrophy (subjects
2 and 3 versus subject 1) strongly suggested dominant-
negative, rather than loss-of-function, effects of the in-
frame mutations.
Characterization of a-II/b-II and a-II/b-III
Heterodimers
The mutations were predicted to affect formation of a/b
spectrin heterodimers, because they were located at the
initial nucleation site of the a/b spectrin heterodimer19
(Figures 1B and 3A). To examine the properties of the a-II
spectrin mutants in the context of dimer formation, we
puriﬁed recombinant WTand the two mutant a-II spectrin
proteins (c.6619_6621 del, p.E2207 del and c.6923_6928
dup, p.R2308_M2309 dup, designated as del mut and dup886 The American Journal of Human Genetics 86, 881–891, June 11,mut, respectively). Both GST pull down and analytical
gel ﬁltration experiments revealed that the two mutants
could form heterodimers with b-II spectrin at comparable
levels to the WT (Figure 3B). Circular dichroism (CD)
spectra indicated no difference of helical content between
WT and mutant a-II spectrin monomers, nor between WT
and mutant a-II/b-II heterodimers (Figures 3C and 3D).
However, CDmelting experiments revealed that the muta-
tions apparently affected the thermostability of a-II/b-II
heterodimers (Figure 3F). Considering the melting curves
of a-II and b-II spectrin monomers (Figure 3E), the melting
transitions of heterodimers in the ranges of 50C–60C and
70C–80Crepresent partial dissociationofheterodimers to
monomers accompanied by denaturation of a local part of
the monomers and complete denaturation, respectively
(Figure 3F). Apparent differences of melting curves in the
50C–60Cand 70C–80C ranges suggested that themuta-
tions alter the stability of a-II/b-II heterodimers.
The effect of the mutations was further clariﬁed by tran-
sient expression in cultured mouse cortical neurons. a-II2010
Figure 4. Mutant a-II Spectrin Causes Aggrega-
tion of a/b Spectrin Heterodimer
(A and B) Expression of the WT and the two
mutant a-II spectrins at 7 DIV. Flag tagged-a-II
spectrin (WT-Flag) showed similar expression to
endogenous a-II spectrin (top, compare with
Figure S2A). However, two mutant a-II spectrins
(del mut-Flag and dupmut-Flag) showed aggrega-
tion predominantly in cell bodies and axons
(arrows), and these aggregations were colocalized
with b-II and b-III spectrins (middle and bottom).
(C and D) Aggregation of endogenous a/b spec-
trin heterodimers were found in LCLs derived
from two subjects harboring SPTAN1 in-frame
mutations. In LCLs of subject 2 (with
c.6619_6621del, p.E2207del) and subject 3
(with c.6923_6928dup, p.R2308_M2309dup),
aggregation of a-II/b-III (C) and a-II/b-II (D) spec-
trin heterodimers were frequently observed
(middle two panels, arrows), while such aggrega-
tion was never observed in subject 1 (top). LCL of
subject 3’s father did not show any such aggrega-
tion (bottom).
The scale bars represent 10 mm. The following
primary antibodies were used: mouse anti-a-II
spectrin (1:400 dilution; clone D8B7; Abcam,
Tokyo, Japan), mouse anti-b-II spectrin (1:600
dilution; clone 42/B-spectrin II; BD Transduction
laboratories, San Jose, CA), rabbit anti-b-II spec-
trin (1:100 dilution; Abcam), rabbit anti-b-III
spectrin (1:400 dilution; Abcam), mouse anti-
Flag M2 (1:1000 dilution; Sigma), and rabbit
anti-DDDDK-Tag (1:2000 dilution; MBL, Nagoya,
Japan).spectrin has been shown to be expressed in mouse
brain, especially in neuronal axons.20 In cultured cortical
neurons, a-II spectrin was expressed at cell extensions
and the periphery,21 overlapping with the expression of
b-II and b-III spectrins (Figure S2). We generated two a-II
spectrin expression vectors: one was a dual expression
vector of C-terminally Flag-tagged a-II spectrin and nuclear
EGFP (Flag-nucEGFP), and the other was an N-terminally
EGFP-tagged (EGFP) a-II spectrin. Tagged WT a-II spectrin
from both vectors showed similar expression to endoge-
nous a-II spectrin (Figure 4A and Figure S2). Notably, the
two mutant a-II spectrins (del mut and dup mut) showed
aggregation, predominantly in cell bodies and axonsThe American Journal of H(Figure 4A, arrows, and Figure S2). Double
immunostaining revealed that these aggre-
gations were colocalized with b-II and b-III
spectrins (Figures 4A and 4B, arrows, and
Figure S2), indicating that unstable a-II/b-
II and a-II/b-III spectrin heterodimers were
involved in the aggregation. Remarkably,
LCLs established from subjects 2 and 3
also showed similar aggregation, while
LCLs of subject 1 and subject 3’s parents
showed no aggregation (Figures 4C and
4D, arrows). These ﬁndings indicated domi-nant-negative effects of the mutations for the integrity of
a-II/b-II and a-II/b-III spectrin heterodimers. Immunos-
taining against b-IV spectrin did not show its involvement
in the mutant aggregation (Figure S2).
Effects of the SPTAN1 Mutations on ankyrinG
and VGSC Clustering at AIS
Spectrins play important roles in clustering speciﬁc inte-
gral membrane proteins at high density in specialized
regions of the plasma membrane.8 To examine the effects
of a/b spectrin heterodimer impairment, protein localiza-
tion at AIS was examined, where ankyrinG and VGSC are
clustered and action potentials are initiated.22,23 At 9uman Genetics 86, 881–891, June 11, 2010 887
DIV, expression of ankyrinG and VGSC were clustered at
AIS when WT Flag-nucEGFP was transfected (Figures 5A
and 5B, top). In contrast, clustering of ankyrinG and
VGSC was disturbed in the presence of extensive a-II
(mut)/b-II and a-II (mut)/b-III spectrin aggregation (Figures
5A and 5B, middle and bottom). Interestingly, whole-cell
current clamp recordings from cortical neurons expressing
mutant a-II spectrins showed impairment of repetitive
action potential elicitation and elevated threshold of
action potential compared with those expressing the WT
(Figure 6A), while there were no signiﬁcant differences in
the passive membrane properties among the genotypes
(Table S3). Recordings of whole-cell sodium currents with
conventional activation and inactivation protocols re-
vealed that expression of the mutants caused a signiﬁcant
depolarizing shift in activation compared with the WT,
indicating increased threshold of sodium currents (Figures
6B and 6C). These mutants did not affect any of the activa-
tion kinetic properties (10%–90% rise time) (Figure 6E), the
voltage dependence of inactivation (Figures 6F and 6G), or
the whole cell capacitance (Table S3). However, peak
sodium current densities were substantially reduced in
cells expressing dup mut or del mut (Figure 6D). Divergent
distribution of VGSC at AIS can increase the action poten-
tial threshold probably resulting from the waste of
charging current across the axonal membrane;24 therefore,
the abnormal spike initiation observed in two mutants
could be caused by the disturbance of VGSC clustering
at AIS.Figure 5. Transient Expression of Mutant a-II Spectrin Led to
Disturbance of AnkyrinG and VGSC Clustering at AIS
Expression of ankyrinG (AnkG) (A) and VGSC (B) at 9 DIV. When
WT a-II spectrin is expressed, neurons showed clustering of AnkG
and VGSC at AIS (top). However, clustering of AnkG and VGSC
were disturbed in the presence of extensive a/b spectrin aggrega-
tion when mutant a-II spectrins (both the del mut and the dup
mut) were expressed (middle and bottom). AIS regions are shown
by dashed lines. The scale bars represent 10 mm. The following
primary antibodies were used: mouse anti-ankyrinG (1:100 dilu-
tion; clone 4G3F8; Santa Cruz Biotechnology, Santa Cruz, CA),
mouse anti-pan sodium channel (for VGSC) (1:100 dilution; clone
K58/35; Sigma), and rabbit anti-DDDDK-Tag (1:2000 dilution;
MBL).Discussion
We have shown that two de novo in-frame mutations of
SPTAN1 cause early-onset WS with spastic quadriplegia,
poor visual attention, and severe developmental delay.
Brain MRI of the two subjects showed severe cerebral hy-
pomyelination, decreased white matter, widespread brain
atrophy including brainstem, hypoplasia and/or atrophy
of the cerebellum, and a thinned and shortened corpus
callosum. On the other hand, mutations of STXBP1 cause
EIEE, and brain MRI of individuals with STXBP1 muta-
tions showed no structural malformations in contrast
with striking structural abnormalities with SPTAN1 muta-
tions.7 Among three subjects harboring SPTAN1 aberra-
tions, subject 1 deleted both SPTAN1 and STXBP1 hetero-
zygously.7 Similar to individuals with STXBP1 mutations,
subject 1 had distinctive features of EIEE, such as early
onset of spasms, suppression-burst pattern on electroen-
cephalogram, transition to West syndrome, and severe
developmental delay.7 Therefore it is likely that haploin-
sufﬁciency of STXBP1 caused EIEE and subsequent WS
in subject 1. However, subject 1 additionally showed
apparent hypomyelination of cerebral cortex and thin
corpus callosum at 12 months of age,14 which appeared
to be distinct from clinical features caused by STXBP1
mutations. Based on these differences, we hypothesized888 The American Journal of Human Genetics 86, 881–891, June 11,that another gene within the deletion may contribute to
severe hypomyelination, and successfully found two de
novo in-frame mutations of SPTAN1 in subject 2 and 3 of2010
Figure 6. Mutant a-II Spectrin Elevated
Action Potential Threshold in Primary
Cultured Cortical Neurons
(A) Left, representative sets of actionpoten-
tial traces recorded from cultured cortical
neurons expressing either WT or mutant
a-II spectrin (del mut or dup mut)-Flag-
nucEGFP during 500 ms injection of depo-
larizing current in þ10 pA increments,
from a holding potential of 60 mV. Right
top, input-output relationship of the
number of evoked action potentials versus
the injected current (WT, n ¼ 7; del mut,
n ¼ 9; dup mut, n ¼ 7). Although there
were no signiﬁcant differences in the
passive membrane properties among each
genotypes (see Table S3), repetitive action
potential elicitation was signiﬁcantly
reduced in the two mutants. Right bot-
tom, representative responses to a series of
subthreshold and suprathreshold depola-
rizing current injections of 10ms duration.
A base holding potential (60 mV) and an
identiﬁed action potential threshold are
indicated by thin and dashed lines, respec-
tively. Note that mutants elevated action
potential threshold compared with the
WT (see Table S3).
(B–G) Recordings of whole-cell sodium
currents with conventional activation
(C–E: WT, n ¼ 11; del mut, n ¼ 10; dup
mut, n ¼ 10) and inactivation protocols
(G: WT, n ¼ 11; del mut, n ¼ 9; dup mut,
n ¼ 10).
(B) Representative sets of sodium current
traces recorded from dissociated cortical
neurons expressing WT and mutant a-II
spectrins.
(C) Voltage dependence of channel activa-
tion measured during voltage steps
between 90 and þ10 mV. Statistical anal-
ysis indicated that delmut and dupmut ex-
hibited signiﬁcant differences in current-
voltage relationship compared with the
WT. Both mutants displayed a signiﬁcant
depolarizing shift in activation compared
with the WT.
(D) Peak current density elicited by test
pulses.Statistical analysis indicatedasignif-
icant reduction in peak current in both
mutants compared with the WT.
(E) Activation kinetics assessed by 10%–90% rise time plotted against test potential forWTandmutants. There were no signiﬁcant differ-
ences amongWTand the two mutants.
(F) Representative sodiumcurrents inneurons expressingWTormutanta-II spectrinunder inﬂuenceof 500ms inactivationprepotentials.
(G) Voltage dependence of inactivation assessed in response to inactivating prepulses between 90 and 35 mV. Statistical analysis
revealed no signiﬁcant differences amongWT and mutants (p ¼ 0.96).
Error bars, SEM. *p< 0.05, **p< 0.01, ***p< 0.001, as compared to theWT. Most of the recorded parameters are summarized in Table S3.group A. Although subject 1 initially showed severe
hypomyelination, the myelination showed catch-up com-
pletion at 4 years of age. These facts suggest that SPTAN1
hemizygosity may have temporary effects on the myelina-
tion. Further reports of microdeletions involving SPTAN1
may give us a clear answer about the contribution of
SPTAN1 hemizygosity to hypomyelination. By contrast,
subjects 2 and 3 showed more severe phenotypes than
subject 1, indicating that the effect of in-frame mutationsThe Amewas dominant negative rather than loss of function. This
idea was supported by the fact that the in-frame mutations
could cause aggregation of a-II/b-II and a-II/b-III spectrin
heterodimers, related to disturbed clustering of ankyrinG
and VGSC at AIS. b-II and b-III spectrins have been shown
to participate in stabilization of membrane proteins and
axonal transport.25,26 Although our study did not detect
aggregation of the a-II/b-IV spectrin heterodimer, which
is essential for stabilization of membrane proteins atrican Journal of Human Genetics 86, 881–891, June 11, 2010 889
AIS,27,28 defective a-II/b-II and a-II/b-III spectrin hetero-
dimers might affect the stability of membrane proteins at
AIS, possibly in combination with disrupting intracellular
transport.
The a-II (mut)/b-II spectrin heterodimers was more
unstable than the a-II (WT)/b-II heterodimers, which
was manifested by CD melting experiments as differences
of melting points at relatively high temperature (50C–
60C and 70C–80C). In general, structural instability
of proteins would lead to aggregate formation. Immuno-
ﬂuorescence analysis in both transiently transfected
primary neuron and LCL derived from two subjects
showed aggregation of a-II/b-II and a-II/b-III spectrin het-
erodimers, suggesting that structual instability of a-II/b-II
and a-II/b-III spectrin heterodimers resulted in the aggre-
gation.
We demonstrated a possible link between a mutant sub-
menbranous scaffolding protein and abnormal AIS integ-
rity. It has been suggested that the levels of ion channels
at AIS are regulated by altering the cytoskeletal scaffolds.22
A recessive mutation of scaffolding protein CASPR2 causes
focal epilepsy.29 Abnormal AIS integrity resulting from
mutant a-II spectrin further underscores the importance
of AIS scaffolds in the pathogenesis of epilepsy and
provides new insights for WS.Supplemental Data
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